BURNABY, B.C., Sept. 6 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. (TSX: CHR - News) has formed a Multiple Sclerosis (MS) Advisory Board to guide the Company’s development of a promising novel treatment for MS. Comprised of nationally and internationally recognized physicians, clinicians and scientists in the MS field, the MS Advisory Board will serve as an independent panel of experts regarding the development of CHR-1103 for the acute treatment of relapses (flares) associated with MS and other follow-on indications related to MS.
Members of the Chromos MS Advisory Board are:
- Jack Antel, MD Professor, Montreal Neurological Institute, McGill University
- Dennis Bourdette, MD Chairman, Department of Neurology and Director of the MS Center of Oregon, Oregon Health and Sciences University
- James Bowen, MD Medical Director of the Multiple Sclerosis Center at Evergreen Healthcare, Kirkland, Washington
- Lorne Kastrukoff, MD Associate Professor, MS Clinic, University of British Columbia, Division of Neurology, Department of Medicine and Brain Research Centre
- Joel Oger, D.en M., FRCPC Professor, University of British Columbia, Medicine, Pathology and Neurosciences
- Leslie P. Weiner, MD Professor of Neurology, Keck School of Medicine, University of Southern California
“We are extremely fortunate and delighted to have the participation of this highly respected and experienced group of experts for the development of our lead product, CHR-1103,” said Alistair Duncan, President and CEO of Chromos. “The ability to access and rely on such a panel of individuals is a tremendous asset for Chromos as we move forward with the clinical development of CHR-1103 for MS.”
CHR-1103 is a monoclonal antibody being developed as an acute treatment for relapses (flares) associated with MS. The drug’s unique mechanism of action has the potential to reduce the severity and duration of a relapse along with stem the residual neurological damage that often accompanies a relapse, thereby slowing the overall progression of the disease.
Chromos has completed a Pre-IND Meeting with the US Food and Drug Administration (FDA) regarding the development of CHR-1103 and anticipates filling an Investigational New Drug (IND) application for CHR-1103 in 2007.
The Chromos MS Advisory Board will be instrumental in guiding the overall clinical development strategy supporting the initial indication for CHR-1103 as an acute treatment for MS relapse, but also follow-on indications surrounding long-term progression of MS and conversion to MS following initial clinical symptoms.
About Chromos
Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders. The Company’s lead program, CHR-1103, is a humanized monoclonal antibody being developed as an acute treatment for MS. Chromos generates revenue to support its product development efforts from its proprietary ACE System technology to engineer production quality cell lines to manufacture biopharmaceutical products, including monoclonal antibodies. For more information visit our website at www.chromos.com.
Risks and Uncertainties
Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos (the “Company”), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with the Company’s operations. Operating risks include (i) the continued availability of capital to finance the Company’s activities; (ii) the Company’s limited cash position, (iii) the ability to successfully obtain proof of the effectiveness of the Company’s technology (iv) the ability to complete and maintain corporate alliances relating to the development and commercialization of the Company’s technology; (v) the ability to obtain and enforce patent and other intellectual property protection for the Company’s technology; (vi) market acceptance of the Company’s technology; (vii) the competitive environment and impact of technological change; (viii) the Company’s ability to attract and retain employees to carry out its business plans and (ix) the timely development and commercialization of any technology or products that are contingent on the completion and maintenance of corporate alliances with third parties. Further details on Chromos’ operating risks can be found in the Company’s Quarterly and Annual Reports to Shareholders.
CONTACT: Joseph Zendegui, Ph.D., Vice President, Corporate Development, Tel: (604) 415-7128, Email:jzendegui@chromos.com, Website: www.chromos.com
Source: Chromos Molecular Systems Inc.
